NASDAQ: LYRA - Lyra Therapeutics, Inc.

छह महीने के लिए लाभप्रदता: -31.96%
भाग प्रतिफल: 0.00%
सेक्टर: Healthcare

पदोन्नति कार्यक्रम Lyra Therapeutics, Inc.

उन्नत शेड्यूल सरल ग्राफ
Financial Markets by TradingView

कंपनी के बारे में Lyra Therapeutics, Inc.

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.

अधिक जानकारी
The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
तुलना सूची में जोड़ें
घड़ी सूची में जोड़ें
पोर्टफोलियो में जोड़ें
मूल्य सूचना जोड़ें

IPO date 2020-05-01
ISIN US55234L1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://lyratherapeutics.com
Цена ао 6.13
प्रति दिन मूल्य परिवर्तन: +5.48% (0.1806)
प्रति सप्ताह मूल्य परिवर्तन: +5.83% (0.18)
प्रति माह मूल्य परिवर्तन: +0.2632% (0.19)
3 महीने में कीमत में बदलाव: -28.3% (0.2657)
छह महीने में कीमत में बदलाव: -31.96% (0.28)
प्रति वर्ष मूल्य परिवर्तन: -96.36% (5.24)
3 वर्षों में मूल्य परिवर्तन: -95.81% (4.55)
5 वर्षों में मूल्य परिवर्तन: 0% (0.1905)
10 वर्षों में मूल्य परिवर्तन: 0% (0.1905)
वर्ष की शुरुआत से मूल्य परिवर्तन: -26.42% (0.2589)
सभी पैरामीटर

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 159.19 1
P/BV 2.77 6
P/E 0 0
EV/EBITDA -3.87 0
कुल: 3.5

क्षमता

नाम अर्थ श्रेणी
ROA, % -43.96 0
ROE, % -70.1 0
कुल: 0

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0 0
कुल: 0

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -0.412 10
कुल: 10

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % 29.83 4
लाभप्रदता Ebitda, % 295.45 10
लाभप्रदता EPS, % -51.03 0
कुल: 6.8
अधिक जानकारी

संस्थानों आयतन शेयर करना, %
Perceptive Advisors LLC 12757562 21.35
Nantahala Capital Management, LLC 8100436 13.56
Vestal Point Capital, LP 3000000 5.02
Point72 Asset Management, L.P. 3000000 5.02
Citadel Advisors Llc 2861255 4.79
Samsara BioCapital, LLC 2780261 4.65
VR Adviser, LLC 2575593 4.31
Rosalind Advisors, Inc. 1888720 3.16
PURA VIDA INVESTMENTS, LLC 1413242 2.37
Ikarian Capital, LLC 1254384 2.1

ETF शेयर करना, % वर्ष के लिए लाभप्रदता, % लाभांश, %
iShares Micro-Cap ETF 0.00348 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00096 38.04 0.6026
ProShares UltraPro Russell2000 0.0003 89.82 1.47873
ProShares Hedge Replication ETF 0.00008 5.92 1.47892
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264



पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Dr. Harlan W. Waksal M.D. Executive Chairman 210.06k 1953 (72 वर्ष)
Dr. Maria Palasis Ph.D. CEO, President & Director 942.7k 1965 (60 साल)
Dr. Carmichael S. Roberts Jr., Ph.D. Co-Founder N/A 1969 (56 साल)
Mr. Jason Cavalier CFO, Treasurer & Secretary 464.11k 1973 (52 वर्ष)
Mr. Ray Knox Vice President of Operations N/A
Ms. Vineeta Belanger Ph.D. Senior Vice President of Clinical Affairs N/A
Mr. Ronan P. O'Brien J.D. Chief Legal Officer 1973 (52 वर्ष)
Dr. Robert Richard Ph.D. Senior Vice President of Technical Operations 1958 (67 साल)
Dr. Robert Kern M.D. Chief Clinical Advisor
Ms. Gloria Cosgrove Senior Vice President of Quality

पता: United States, Watertown. MA, 480 Arsenal Way - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://lyratherapeutics.com